These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 38940663)

  • 1. Research progress in tumor angiogenesis and drug resistance in breast cancer.
    Mou J; Li C; Zheng Q; Meng X; Tang H
    Cancer Biol Med; 2024 Jun; 21(7):571-85. PubMed ID: 38940663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Therapeutic Strategies for Lung and Breast Cancers through Understanding the Anti-Angiogenesis Resistance Mechanisms.
    Ramadan WS; Zaher DM; Altaie AM; Talaat IM; Elmoselhi A
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31952335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.
    Trédan O; Lacroix-Triki M; Guiu S; Mouret-Reynier MA; Barrière J; Bidard FC; Braccini AL; Mir O; Villanueva C; Barthélémy P
    Target Oncol; 2015 Jun; 10(2):189-98. PubMed ID: 25185646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis as a hallmark of solid tumors - clinical perspectives.
    Majidpoor J; Mortezaee K
    Cell Oncol (Dordr); 2021 Aug; 44(4):715-737. PubMed ID: 33835425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenesis: Opening a new window for immunotherapy.
    Guo F; Cui J
    Life Sci; 2020 Oct; 258():118163. PubMed ID: 32738363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.
    Lindholm EM; Kristian A; Nalwoga H; Krüger K; Nygård S; Akslen LA; Mælandsmo GM; Engebraaten O
    Mol Oncol; 2012 Aug; 6(4):418-27. PubMed ID: 22521242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignancies.
    Zhao C; Zeng Y; Kang N; Liu Y
    Drug Dev Res; 2024 Sep; 85(6):e22257. PubMed ID: 39245913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy.
    Lan M; Lu W; Zou T; Li L; Liu F; Cai T; Cai Y
    Cell Mol Life Sci; 2021 Mar; 78(5):2105-2129. PubMed ID: 33386887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment.
    Hameed S; Bhattarai P; Dai Z
    Sci China Life Sci; 2018 Apr; 61(4):380-391. PubMed ID: 29607461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?
    Bozza C; Fontanella C; Buoro V; Mansutti M; Aprile G
    Expert Rev Clin Pharmacol; 2015 Mar; 8(2):251-65. PubMed ID: 25597501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic therapy in the management of breast cancer.
    Wu Y; Sun WL; Feng JF
    Asia Pac J Clin Oncol; 2013 Jun; 9(2):110-6. PubMed ID: 22898270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taohong Siwu decoction enhances the chemotherapeutic efficacy of doxorubicin by promoting tumor vascular normalization.
    Cheng Y; Li J; Feng X; Wu Y; Wu X; Lau BWM; Ng SSM; Lee SM; Seto SW; Leung GP; Hu Y; Fu C; Zhang S; Zhang J
    Phytomedicine; 2024 Nov; 134():155995. PubMed ID: 39270591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies.
    Melaiu O; Vanni G; Portarena I; Pistolese CA; Anemona L; Pomella S; Bei R; Buonomo OC; Roselli M; Mauriello A; Barillari G
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast tumour angiogenesis.
    Fox SB; Generali DG; Harris AL
    Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review).
    Salinas-Vera YM; Marchat LA; Gallardo-Rincón D; Ruiz-García E; Astudillo-De La Vega H; Echavarría-Zepeda R; López-Camarillo C
    Int J Mol Med; 2019 Feb; 43(2):657-670. PubMed ID: 30483765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic therapies in breast cancer.
    Sarmiento R; D'Andrea MR; Cacciamani F; Salerno F; Gasparini G
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1334-45. PubMed ID: 19943205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.
    Rapisarda A; Melillo G
    Nat Rev Clin Oncol; 2012 Apr; 9(7):378-90. PubMed ID: 22525710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer.
    Ademuyiwa FO; Miller KD
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S151-6. PubMed ID: 19158035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic strategies, compounds, and early clinical results in breast cancer.
    Morabito A; Sarmiento R; Bonginelli P; Gasparini G
    Crit Rev Oncol Hematol; 2004 Feb; 49(2):91-107. PubMed ID: 15012971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.